Argen-X (0QW0)
London Stock Exchange · UK · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 778.10 |
|---|---|
| 52-week range | 569.00 – 924.70 |
| Return, 1 month / 3 months | −7.9% / −2.4% |
| Return, 1 year / 3 years | +10.4% / +76.9% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 47 |
| Volatility (1 year) | 37.7% |
| Worst drawdown (1 year) | -27.4% |
| Average daily value traded | 22.54M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Argenx is a biopharmaceutical company that develops antibody-based medicines for people with severe autoimmune diseases. Its main product is an antibody therapy designed to reduce harmful autoantibodies, and it is used to treat conditions such as myasthenia gravis and other immune disorders. The company carries out research, clinical development and commercial activities, serving patients and healthcare providers in several countries. Argenx is based in the Netherlands, with additional operations in Belgium and the United States.
The shares are listed on the London Stock Exchange in UK under the code 0QW0, and the price on this page is in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Argen-X (0QW0) trades on the London Stock Exchange in UK. It last closed at EUR 778.10 on 27 October 2026.
Its price-based Market X-Ray is 64 out of 100 (a fair price profile), ranking 1,012 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 10.4% and over the last three months it fell 2.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 68 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 5.1% | ||
| From 52-week high | -14.7% | ||
| Momentum | 64 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -2.4% | ||
| 6-month return | 15.3% | ||
| 12-month return, skipping the last month | 19.8% | ||
| Stability (higher is calmer) | 50 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 37.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -27.4% | ||
| Liquidity | 80 · Strong | Trades actively. | |
| Average daily value traded | 22.54M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +1.0% |
|---|---|
| 1 month | −7.9% |
| 3 months | −2.4% |
| 6 months | +15.3% |
| 1 year | +10.4% |
| 3 years | +76.9% |
| 5 years | +223.8% |
Signals
| 50-day / 200-day average | 833.59 / 740.36 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 28.64 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.